By Brian T. Horowitz
Ransomware attacks cost the healthcare industry $20.8 billion in downtime in 2020, which is double the number from 2019. Here's why cybersecurity experts say 2020 offered a perfect storm for cybercriminals and a critical tipping point for the cyber arms race.
read more
By Eric Sagonowsky
While COVID-19 shots have proven effective in clinical trials—and in the real world, too—relatively little is known about how well they work in children and pregnant women. Pfizer, Moderna and J&J aim to change that. The leading players are setting out with studies in children just as new data support mRNA shots in pregnant women.
read more
By Paige Minemyer
Few employers believe vaccines should be mandatory before employees return to the workplace, according to a new survey from Willis Towers Watson.
read more
By Fraiser Kansteiner
BioNTech won approval from the European Medicines Agency to start making and supplying partners with vaccine drug product from the Marburg, Germany, facility it picked up from Novartis last fall. BioNTech is gunning to deliver 250 million doses from the site in the first half of the year, and the plant could ultimately hit annual capacity of 1 billion doses.
read more
By Nick Paul Taylor
The University of Oxford has begun a phase 1 clinical trial of a nasal spray formulation of its AstraZeneca-partnered COVID-19 vaccine.
read more
By Robert King
The Senate passed legislation Thursday intended to extend through 2021 a moratorium on a 2% cut to Medicare payments that was installed under the sequester.
read more
By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky
After a slow start for Johnson & Johnson's vaccine rollout, 11 million more doses are on the way. Plus, GSK and Vir submitted their antibody to the FDA for a potential emergency authorization. And more.
read more
